

<p style="text-align: center;">IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</p>	<i>Application Number</i>	
	<i>Filing Date</i>	
	<i>First Named Inventor</i>	Clive Graham COPLEY
	<i>Group Art Unit</i>	
	<i>Examiner Name</i>	
	<i>Attorney Docket Number</i>	1991-209
<p><i>Title of the Invention:</i> MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM</p>		

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to examination of the above-referenced patent application, please enter the amendments summarized below:

Please add a new paragraph before the first paragraph on page 1 as shown below.

Please add the Abstract of the Disclosure as the final page of the application. A separate page with the Abstract of the Disclosure is also attached at the end of this document.

Please cancel claims 1-7, 11-13 and 15 and amend claims 8, 9 and 14 and add new claims 16-22. There are no amendments to claim 10.

Marked-up copies of the original text of the amended claims is attached to this amendment. Material inserted is indicated by redlining (insertion) and material deleted is indicated by strike-out (strike-out).

Changes to Specification

On page 1, after the title and before the first paragraph, please insert the following paragraph:

This application is a divisional of Serial No. 09/171,945, filed October 29, 1998.

Added Abstract of the Disclosure

ABSTRACT OF THE DISCLOSURE

An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DBYMH CDR2 WIDPENGDT EYAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

Clean Copy of All Pending Claims

8 (amended). A polynucleotide sequence encoding a polypeptide comprising an anti-CEA antibody ("806.077 Ab") comprising complementarity determining regions (CDRs) in which the CDRs comprise the following sequences:

a) heavy chain

CDR1 DNYMH (SEQ ID NO: 29)

CDR2 WIDPENGDT E YAPKFRG (SEQ ID NO: 31)

CDR3 LIYAGYLAMD Y (SEQ ID NO: 32); and

b) light chain

CDR1 SASSSVTYMH (SEQ ID NO: 26)

CDR2 STSNLAS (SEQ ID NO: 27)

CDR3 QQRSTYPLT (SEQ ID NO: 28)

9(amended). A vector comprising a polynucleotide as defined in claim 8, 20, 21 or 22.

10. A host cell transformed with a polynucleotide sequence as defined in claim 8 or a transgenic non-human animal or transgenic plant developed from the host cell.

14(amended). A method of making an antibody as defined in claim 8 which comprises:

subjecting a transgenic non-human mammal or a transgenic plant as defined in claim 10 to conditions conducive to expression of the antibody.

16(new). A polynucleotide sequence encoding a polypeptide comprising an antibody conjugate comprising an antibody as defined in claim 8 and an effector moiety.

17(new). A vector comprising a polynucleotide sequence as defined in claim 16.

18(new). A host cell transformed with a polynucleotide sequence as defined in claim 16 or a transgenic non-human animal or transgenic plant developed from the host cell.

19(new). A method of making a conjugate as defined in claim 16, which comprises:
subjecting a host cell, a transgenic non-human mammal or a transgenic plant as defined in claim 18 to conditions conducive to expression of the antibody conjugate.

20(new). A polynucleotide sequence encoding a polypeptide comprising an antibody as defined in claim 8, wherein the heavy chain CDRs 1 and 3 are further defined as:

CDR1 FNIKDNYMH (SEQ ID NO: 30); and
CDR3 HVLIYAGYLA MDY (SEQ ID NO: 33).

21(new). A polynucleotide sequence encoding a polypeptide comprising an antibody as defined in claim 8, said antibody comprising the following, optionally humanized, structure:

a heavy chain variable region sequence (SEQ ID NO:11)

EVQLQQSGAE LVRSGASVKL SCTASGFNIK DNYMHWVKQR	40
PEQGLEWIAW IDPENGDT EY APKFRGKATL TADSSSNTAY	80
LHLSSLTSED TAVYYCHVLI YAGYLA MDYW GQGTSVAVSS	120

and

a light chain variable region sequence (SEQ ID NO:9)

DIELTQSPAI MSASPGEKVT ITCSASSSVT YMHWFQQKPG	40
TSPKLWIYST SNLASGV PAR FSGSGSGTSY SLTISRMEAE	80
DAATYYCQQR STYPLTFGAG TKLELKRA	108

22(new). A polynucleotide sequence encoding a polypeptide comprising a humanized antibody as defined in claim 21, said antibody comprising at least one of the following sequence:

- a heavy chain variable region sequence which is VH1 (SEQ ID NO:55);
 - a light chain variable region sequence which is VK4 (SEQ ID NO:71);
 - a human CH1 heavy chain IgG3 constant region;
 - a human kappa light chain CL region; and
 - a human IgG3 hinge region;
- optionally in the form of a f(ab')₂ fragment.

REMARKS

This application is filed as a divisional of USSN 09/171,945. This amendment includes claims cancelled in the parent application. No new matter has been added with this amendment.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Barbara G. Ernst, Reg. No. 30,377				
SIGNATURE	Barbara G. Ernst		DATE	July 23, 2001	
Address	Rothwell, Figg, Ernst & Manbeck Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

Attachments: Marked-Up Copies of Amendments

Amended Claims: Version with markings to show changes made

8. A polynucleotide sequence ~~capable of encoding a polypeptide of comprising~~ an anti-CEA antibody ("806.077 Ab") or a conjugate as defined in any preceding claim comprising complementarity determining regions (CDRs) in which the CDRs comprise the following sequences:

a) heavy chain

CDR1 DNYMH (SEQ ID NO: 29)

CDR2 WIDPENGDT E YAPKFRG (SEQ ID NO: 31)

CDR3 LIYAGYLAMD Y (SEQ ID NO: 32); and

b) light chain

CDR1 SASSSVTYMH (SEQ ID NO: 26)

CDR2 STSNLAS (SEQ ID NO: 27)

CDR3 QQRSTYPLT (SEQ ID NO: 28)

9. A vector comprising a polynucleotide as defined in claim 8, 20, 21 or 22.

14. A method of making an antibody or conjugate as defined in any preceding claim 8 which comprises:

a) ~~subjecting a host cell; a transgenic non-human mammal or a transgenic plant as defined in claim 10; or the hybridoma of claim 11; to conditions conducive to expression; and optionally secretion; of the antibody or conjugate; and optionally~~

~~b) at least partially purifying the antibody or conjugate.~~

ABSTRACT OF THE DISCLOSURE

An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DBYMH CDR2 WIDPENGDT EYAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

806.077